Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study
Feb 19, 2013 - Gilead Sciences today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus infection who failed prior treatment.
Join the discussion below, or Read more at Drugs.com.
#1 Feb 19, 2013
Thank God, thank God and good doctors
Add your comments below
|Should state mandate immunizations? New require... (May '11)||Aug 4||JazzySam||9,780|
|Gay men can now donate blood three months after...||Jul 24||Darby||4|
|Rebuttal over Cochrane Review of DAAs-What is t...||Jul '17||hcvnewdrugs||1|
|Scientific Evidence and the EU Court||Jul '17||VAERS NVICP||1|
|The Liver - Super Foods & Supplements||Jun '17||hcvnewdrugs||1|
|EU court: Vaccines can be blamed for illnesses ...||Jun '17||RIGHT ON||2|
|Burlington dental patients told to get tested f...||Jun '17||Lenny||1|
Find what you want!
Search Hepatitis Forum Now
Copyright © 2017 Topix LLC